FindTrial
Sign In

Ion beam therapy with concurrent chemotherapy using Gemcitabine for unresectable pancreatic cancer, Phase I/II study

Ion beam therapy with concurrent chemotherapy using Gemcitabine for unresectable pancreatic cancer, Phase I/II study - Ion beam therapy with concurrent chemotherapy using Gemcitabine for unresectable pancreatic cancer, Phase I/II study

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002173
Enrollment
30
Registered
2009-07-14
Start date
2009-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Ion beam therapy(proton therapy, carbon-ion therapy)

Sponsors

Department of Radiology, Hyogo Ion Beam Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: unresectable pancreatic cancer

Exclusion criteria

Exclusion criteria: distal metastases

Design outcomes

Primary

MeasureTime frame
QOL survival time—

Countries

Japan

Contacts

Public ContactKazuki Terashima

Hyogo Ion Beam Medical Center Department of Radiology

k.terashima@hibmc.shingu.hyogo.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026